Seraphim Space Investment Trust (LSE: SSIT) leans on ICEYE re-rating and SpaceX IPO tailwind to consolidate FTSE 250 entry
Read More Healthcare Industry News OncoSil Medical (OSL:ASX) has pancreatic cancer data momentum, but investors now need adoption proof OSL has TRIPP-FFX data, TGA approval and FDA pathway momentum. The bigger test is whether OncoSil can turn evidence into adoption. byVenkateshJune 10, 2026